JP2023529001A5 - - Google Patents
Info
- Publication number
- JP2023529001A5 JP2023529001A5 JP2022576335A JP2022576335A JP2023529001A5 JP 2023529001 A5 JP2023529001 A5 JP 2023529001A5 JP 2022576335 A JP2022576335 A JP 2022576335A JP 2022576335 A JP2022576335 A JP 2022576335A JP 2023529001 A5 JP2023529001 A5 JP 2023529001A5
- Authority
- JP
- Japan
- Prior art keywords
- solid oral
- oral composition
- rabeximod
- composition according
- dosage form
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP20179277 | 2020-06-10 | ||
| EP20179279.3 | 2020-06-10 | ||
| EP20179239 | 2020-06-10 | ||
| EP20179239.7 | 2020-06-10 | ||
| EP20179279 | 2020-06-10 | ||
| EP20179277.7 | 2020-06-10 | ||
| EP20180706.2 | 2020-06-18 | ||
| EP20180706 | 2020-06-18 | ||
| PCT/EP2021/065705 WO2021250204A1 (en) | 2020-06-10 | 2021-06-10 | Oral formulation comprising a crystalline form of rabeximod |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023529001A JP2023529001A (ja) | 2023-07-06 |
| JP2023529001A5 true JP2023529001A5 (enExample) | 2024-06-18 |
Family
ID=76305939
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022576335A Pending JP2023529001A (ja) | 2020-06-10 | 2021-06-10 | 結晶形のラベキシモドを含む経口製剤 |
| JP2022575226A Pending JP2023529877A (ja) | 2020-06-10 | 2021-06-10 | 結晶形のラベキシモドの調製方法 |
| JP2022575829A Pending JP2023533662A (ja) | 2020-06-10 | 2021-06-10 | 関節リウマチの治療におけるラベキシモド |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022575226A Pending JP2023529877A (ja) | 2020-06-10 | 2021-06-10 | 結晶形のラベキシモドの調製方法 |
| JP2022575829A Pending JP2023533662A (ja) | 2020-06-10 | 2021-06-10 | 関節リウマチの治療におけるラベキシモド |
Country Status (8)
| Country | Link |
|---|---|
| US (3) | US12594274B2 (enExample) |
| EP (3) | EP4164616A1 (enExample) |
| JP (3) | JP2023529001A (enExample) |
| KR (3) | KR20230022882A (enExample) |
| CN (4) | CN115697308A (enExample) |
| AU (3) | AU2021290174A1 (enExample) |
| CA (3) | CA3181637A1 (enExample) |
| WO (3) | WO2021250199A1 (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2023529001A (ja) | 2020-06-10 | 2023-07-06 | シクソン エービー | 結晶形のラベキシモドを含む経口製剤 |
| US11643415B1 (en) * | 2021-12-09 | 2023-05-09 | Cyxone Ab | Rabeximod compounds |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE8600260D0 (sv) | 1986-01-21 | 1986-01-21 | Lundblad Leif | Substituerade indolokinoxaliner |
| SE504289C2 (sv) * | 1994-06-23 | 1996-12-23 | Leif J I Lundblad | Användning av vissa indolo-2,3b-kinoxaliner för framställning av ett läkemedel för inhibering av enzymet HIV-integras |
| JPH08165278A (ja) | 1994-12-14 | 1996-06-25 | Kawaken Fine Chem Co Ltd | １−置換トリプタミン化合物の製造方法 |
| SE504862C2 (sv) | 1994-12-27 | 1997-05-20 | Leif J I Lundblad | Användning av vissa indolo-§2,3b¤-kinoxaliner för framställning av ett läkemedel för skydd av DNA i initieringsfasen och/eller promotionsfasen av karcinogenes och för förhindrande av oxidativ stress i patienter med sjukdomar relaterade till fria radikaler |
| DE19516804A1 (de) * | 1995-05-08 | 1996-11-14 | Hoechst Ag | Isoindolinpigmente auf Basis von Aminochinoxalindionen |
| SE516067C2 (sv) | 2000-02-18 | 2001-11-12 | Lundblad Leif J I | Användning av en förening för framställning av ett läkemedel |
| US6333327B2 (en) | 2000-02-18 | 2001-12-25 | Leif J. I. Lundblad | Method for the treatment of Multiple Sclerosis |
| TW200410921A (en) * | 2002-11-25 | 2004-07-01 | Hoffmann La Roche | Mandelic acid derivatives |
| ATE382623T1 (de) * | 2004-06-09 | 2008-01-15 | Hoffmann La Roche | Octahydropyrrolo(3,4-c)pyrrolderivate und deren verwendung als antivirale mitteln |
| SE527639C2 (sv) | 2004-06-17 | 2006-05-02 | Oxypharma Ab | Alkylsubstituerade indolokinoxaliner |
| CN101558038B (zh) * | 2006-11-30 | 2013-05-01 | 国立大学法人东京工业大学 | 姜黄素衍生物 |
| CN102115457B (zh) | 2011-03-05 | 2012-11-21 | 太原理工大学 | 一种n-乙基咔唑的制备方法 |
| WO2013182905A2 (en) * | 2012-06-05 | 2013-12-12 | Jonas Axelsson | Mechanism, diagnostic, and treatments for complications of renal failure |
| WO2014140321A1 (en) | 2013-03-15 | 2014-09-18 | Vironova Ab | Antiviral indolo[2,3-b]quinoxaline |
| EP3302442B1 (en) | 2015-06-03 | 2024-10-16 | Triastek, Inc. | Dosage forms and use thereof |
| CN105061432B (zh) | 2015-07-16 | 2017-09-29 | 河北大学 | 6H‑吲哚[2,3‑b]喹喔啉衍生物、药物组合物及其制备和应用 |
| TWI721483B (zh) * | 2018-07-13 | 2021-03-11 | 美商基利科學股份有限公司 | 吡咯并[1,2-b]嗒𠯤衍生物 |
| WO2021250196A1 (en) | 2020-06-10 | 2021-12-16 | Cyxone Ab | New use of rabeximod |
| JP2023529001A (ja) | 2020-06-10 | 2023-07-06 | シクソン エービー | 結晶形のラベキシモドを含む経口製剤 |
| US11643415B1 (en) * | 2021-12-09 | 2023-05-09 | Cyxone Ab | Rabeximod compounds |
-
2021
- 2021-06-10 JP JP2022576335A patent/JP2023529001A/ja active Pending
- 2021-06-10 WO PCT/EP2021/065697 patent/WO2021250199A1/en not_active Ceased
- 2021-06-10 AU AU2021290174A patent/AU2021290174A1/en not_active Abandoned
- 2021-06-10 EP EP21730626.5A patent/EP4164616A1/en active Pending
- 2021-06-10 EP EP21733745.0A patent/EP4165043A1/en active Pending
- 2021-06-10 WO PCT/EP2021/065705 patent/WO2021250204A1/en not_active Ceased
- 2021-06-10 CN CN202180042114.0A patent/CN115697308A/zh active Pending
- 2021-06-10 EP EP21731797.3A patent/EP4164650A1/en active Pending
- 2021-06-10 CN CN202510521204.8A patent/CN120383602A/zh active Pending
- 2021-06-10 KR KR1020227045213A patent/KR20230022882A/ko active Pending
- 2021-06-10 US US18/000,943 patent/US12594274B2/en active Active
- 2021-06-10 US US18/000,945 patent/US12673056B2/en active Active
- 2021-06-10 JP JP2022575226A patent/JP2023529877A/ja active Pending
- 2021-06-10 CA CA3181637A patent/CA3181637A1/en active Pending
- 2021-06-10 AU AU2021290173A patent/AU2021290173A1/en active Pending
- 2021-06-10 WO PCT/EP2021/065694 patent/WO2021250197A1/en not_active Ceased
- 2021-06-10 CA CA3181646A patent/CA3181646A1/en active Pending
- 2021-06-10 AU AU2021289006A patent/AU2021289006A1/en active Pending
- 2021-06-10 CN CN202180041778.5A patent/CN115698010A/zh active Pending
- 2021-06-10 CN CN202180042179.5A patent/CN115768431A/zh active Pending
- 2021-06-10 JP JP2022575829A patent/JP2023533662A/ja active Pending
- 2021-06-10 KR KR1020227045212A patent/KR20230022881A/ko active Pending
- 2021-06-10 CA CA3181629A patent/CA3181629A1/en active Pending
- 2021-06-10 KR KR1020227045211A patent/KR20230022880A/ko active Pending
- 2021-12-22 US US17/559,057 patent/US20220133717A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2006516570A5 (enExample) | ||
| RU99107283A (ru) | Не содержащие лактозы, негигроскопичные и безводные фармацевтические препараты дескарбоэтоксилоратадина | |
| JP2016540021A5 (enExample) | ||
| AU2013248685A1 (en) | Orally available pharmaceutical formulation suitable for improved management of movement disorders | |
| MXPA03011314A (es) | Formulacion farmaceutica para la administracion eficiente de apomorfina, 6ar-(-)-n-propil-norapomorfina y sus derivados y pro-farmacos de los mismos. | |
| FI3710000T3 (fi) | Tradipitantti käytettäväksi gastropareesin hoidossa | |
| EP0078079B1 (en) | Nitrofurantoin dosage form | |
| CN117281788A (zh) | 双层药物片剂制剂 | |
| JPH10504557A (ja) | イブプロフェンおよびコデイン含有の改良された医薬処方 | |
| WO2021129735A1 (zh) | 一种固体制剂及其制备方法和用途 | |
| HUP0000850A2 (hu) | Balszalazidszármazékokat tartalmazó új gyógyszerforma | |
| CY1653A (en) | Pharmaceutical compositions with analgesic properties and the preparation and use thereof | |
| US4466960A (en) | Analgesic-diuretic compositions | |
| JP7209537B2 (ja) | 固形医薬製剤 | |
| DK164638B (da) | Kombinationspraeparat af pyrimido-pyrimidiner og acetylsalicylsyre og/eller deres farmaceutisk acceptable salte, fremgangsmaade til dets fremstilling samt anvendelse af pyrimido-pyrimidiner og acetylsalicylsyre og/eller salte deraf sammen med farmaceutiske baerere til fremstilling af et kombinationspraeparat | |
| HU186855B (en) | Process for producing galenic pharmaceutical compositions with controlled solving-out of active agents | |
| JP2014114253A (ja) | 生薬を含有する鎮痛抗炎症用組成物 | |
| CN101416959A (zh) | 15-亚甲基取代穿心莲内酯衍生物在制备抗炎解热镇痛药物中的用途 | |
| JP2022508236A5 (enExample) | ||
| JP2023510965A5 (enExample) | ||
| TW200911247A (en) | Use of 4-cyclopropylmethoxy-N-(3,5-dichloro-1-oxidopyridin-4-yl)-5-(methoxy)pyridine-2-carboxamide for preparing a medicament for use in the treatment of motor disorders related to parkinson's disease | |
| BRPI0908988A2 (pt) | formulação galênica oral incluindo cetorolaco e vitaminas do complexo b, em que a vitamina b6 está em uma camada externa separada do resto dos princípios ativos | |
| JP2023533662A5 (enExample) | ||
| FI3886857T3 (fi) | Montelukasti erosiivisen käden nivelrikon hoitoon | |
| CA2798420A1 (en) | Combination of an nsaid and an amino acid |